Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Non Operating Investment Income (2021 - 2022)

Immuneering has reported Non Operating Investment Income over the past 2 years, most recently at $112353.0 for Q4 2022.

  • Quarterly results put Non Operating Investment Income at $112353.0 for Q4 2022, up 353.86% from a year ago — trailing twelve months through Dec 2022 was $18889.0 (changed N/A YoY), and the annual figure for FY2022 was $18889.0, up 138.54%.
  • Non Operating Investment Income for Q4 2022 was $112353.0 at Immuneering, up from $39088.0 in the prior quarter.
  • Over the last five years, Non Operating Investment Income for IMRX hit a ceiling of $112353.0 in Q4 2022 and a floor of -$118386.0 in Q1 2022.